Global Abdominal Aortic Aneurysm Drug Market Size By Type (BSN-908, Canakinumab), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Abdominal Aortic Aneurysm (AAA) Drug Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 2.3 billion by 2031, growing at a CAGR of 9.6% during the forecast period from 2023 to 2031. The rising incidence of aortic aneurysms due to aging populations, increased smoking prevalence, and hypertension is fueling the demand for advanced pharmacological solutions. The market is witnessing growth as drug therapies—especially those targeting inflammation and vascular health—are increasingly being explored as adjuncts or alternatives to surgical intervention.

Drivers:

1. Rising Geriatric Population and Prevalence of Hypertension:

Elderly individuals are more prone to AAA due to vascular degeneration, with hypertension further exacerbating the risk. The growing global geriatric population is a key driver for long-term pharmaceutical management strategies for AAA.

2. Advances in Drug Research for Aortic Wall Stabilization:

Significant advancements in anti-inflammatory agents, matrix metalloproteinase inhibitors, and beta-blockers have shown promise in reducing aneurysm expansion, offering potential for preventive pharmacotherapy.

3. Increased Screening and Early Detection Rates:

The widespread implementation of abdominal ultrasound screening programs in high-risk populations has increased the detection of asymptomatic AAAs, thereby expanding the patient pool eligible for medical therapy.

Restraints:

1. Limited Approved Drug Therapies:

There are currently no FDA-approved drugs specifically indicated for treating AAA, restricting the scope of pharmaceutical intervention. Off-label use remains the predominant strategy, affecting market penetration.

2. Preference for Surgical Repair in Large AAAs:

Despite the growth in drug research, endovascular and open surgical repair remain the gold standards for large or ruptured AAAs, limiting the uptake of pharmacological management options.

Opportunity:

1. Development of Disease-Modifying Therapeutics:

There is a major opportunity for pharmaceutical companies to develop disease-modifying therapies that can slow or halt aneurysm progression, filling a critical unmet medical need and expanding the market.

2. Strategic Collaborations and Clinical Trials:

R&D collaborations between academic institutions, biotech firms, and major pharmaceutical players can accelerate clinical trials for novel AAA drugs, pushing the market into a new era of therapeutic options.

Market by System Type Insights:

The AAA Drug Market can be segmented based on drug class, with anti-inflammatory agents emerging as the dominant segment in 2023. These drugs, particularly doxycycline and statins, are widely researched for their ability to inhibit proteolytic enzymes involved in aortic wall degradation. Additionally, beta-blockers and angiotensin II receptor blockers (ARBs) are gaining traction for their potential to manage aneurysm growth by controlling blood pressure and reducing aortic wall stress.

Market by End-use Insights:

Hospitals dominated the end-use segment in 2023, accounting for more than 45% of total revenue. Hospitals play a crucial role in diagnosis, risk stratification, and initiating pharmacological interventions for patients with small AAAs. Clinics and outpatient facilities are also seeing growth, driven by the trend toward non-invasive and chronic disease management models.

Market by Regional Insights:

North America held the largest share of the AAA drug market in 2023, owing to high awareness, extensive screening programs, and a robust healthcare infrastructure. Europe followed closely, with proactive public health initiatives targeting aortic aneurysms. However, the Asia-Pacific region is expected to grow at the fastest CAGR, driven by increasing healthcare expenditure, rising life expectancy, and growing demand for non-invasive vascular therapies.

Competitive Scenario:

Key players in the Global Abdominal Aortic Aneurysm Drug Market include Pfizer Inc., AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, AbbVie Inc., Merck & Co., Inc., Johnson & Johnson, Sanofi, Amgen Inc., and Bristol-Myers Squibb Company. These companies are investing in early-phase trials and pipeline development focused on vascular inflammation and remodeling.

Key Market Developments:

2023: Novartis AG initiated a Phase II trial for an anti-inflammatory biologic aimed at halting AAA progression.

2024: Pfizer Inc. announced a research collaboration with a leading vascular research institute to explore ARB-enhanced AAA therapy.

2025: AstraZeneca PLC received breakthrough therapy designation for a novel oral MMP inhibitor targeting abdominal aortic aneurysms.

Scope of Work – Global Abdominal Aortic Aneurysm Drug Market

Report Metric Details

Market Size (2023) USD 1.1 billion

Projected Market Size (2031) USD 2.3 billion

CAGR (2023–2031) 9.6%

Market Segments By Drug Class, By End-use, By Region

Growth Drivers Rising geriatric population, Advances in drug research, Increased screening

Opportunities Development of disease-modifying therapies, Strategic collaborations

FAQs:

1. What is the current market size of the Global Abdominal Aortic Aneurysm Drug Market?

The market size was valued at USD 1.1 billion in 2023.

2. What is the major growth driver of the Global Abdominal Aortic Aneurysm Drug Market?

Key growth drivers include the rising geriatric population, increased prevalence of hypertension, and advancements in anti-inflammatory drug research.

3. Which is the largest region during the forecast period in the Global Abdominal Aortic Aneurysm Drug Market?

North America held the largest market share in 2023 and is expected to maintain its dominance during the forecast period.

4. Which segment accounted for the largest market share in the Global Abdominal Aortic Aneurysm Drug Market?

The Anti-inflammatory Drug segment held the largest share in 2023 due to its potential in slowing aneurysm progression.

5. Who are the key market players in the Global Abdominal Aortic Aneurysm Drug Market?

Key players include Pfizer Inc., AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, and AbbVie Inc.

Let me know if you'd like this exported into a Word document or formatted for a presentation.